91Ó°ÊÓ

For exercises 12.51-12.53, evaluate the study based on the extracts from the study abstracts by answering the following questions: a. What is the research question that the investigators are trying the answer? b. What is their answer to the research question? c. What were the methods they used to collect data? d. Is the conclusion appropriate for the methods used to collect data? e. To what population do the conclusions apply? f. Have the results been replicated (reproduced) in other articles? According to the National Institute of Mental Health, Social Anxiety Disorder (SAD) is a mental health disorder that affects up to \(7 \%\) of the population of the United States. Because many SAD patients experience inadequate symptom relief with available treatments, researchers in this study investigated the use of ketamine to treat SAD patients (Taylor et al. 2018 ). Read the following excerpts from the study abstract and evaluate the study using the given questions. Methods: We conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adults with Social Anxiety Disorder and compared the effects between intravenous ketamine and placebo on social phobia symptoms. Ketamine and placebo infusions were administered in a random order with a 28 -day washout period between infusions. Ratings of anxiety were assessed 3 -hours post-infusion and followed for 14 days. Outcomes were blinded ratings on the Liebowitz Social Anxiety Scale (LSAS) and self-reported anxiety on a visual analog scale (VAS-Anxiety). Results: We found ketamine resulted in a significantly greater reduction in anxiety relative to placebo on the \(\operatorname{LSAS}(p=0.01)\) but not the VAS-Anxiety \((p=0.95)\). Participants were significantly more likely to exhibit a treatment response after ketamine infusion relative to placebo in the first 2 weeks following infusion measured on the LSAS (33.33\% response ketamine vs \(0 \%\) response placebo, \(p=0.025\) ) and VAS (88.89\% response ketamine vs \(52.94 \%\) response placebo, \(p=0.034\) ). Conclusion: This trial provides initial evidence that ketamine may be effective in reducing anxiety.

Step by step solution

01

Identify the research question

The research question the investigators are trying to answer is: Can ketamine be used to effectively treat patients with Social Anxiety Disorder?

02

Identify the answer to the research question

The researchers found that ketamine resulted in a significant reduction in anxiety levels compared to a placebo.

03

Identify the data collection methods

The data collection methods include a double-blind, randomized, placebo-controlled cross-over trial where the effects between intravenous ketamine and placebo were compared. Ratings of anxiety were assessed 3 hours post-infusion and followed up for 14 days. Outcomes were assessed based on the Liebowitz Social Anxiety Scale (LSAS) and self-reported anxiety on a Visual Analog Scale (VAS).

04

Evaluate the conclusion against the data collection methods

Given the data collection methods used, which was a fairly robust experimental design, the conclusion that ketamine may be effective in reducing anxiety seems appropriate.

05

Determine the population to which the study applies

The conclusions apply to adults with Social Anxiety Disorder, possibly those residing in the United States since the initial remark from the National Institute of Mental Health mentions the percentage of people with SAD in the US.

06

Determine if the results have been replicated

The exercise does not provide information on whether the results have been replicated in other articles.

Unlock Step-by-Step Solutions & Ace Your Exams!

• Full Textbook Solutions

  Get detailed explanations and key concepts

• Unlimited Al creation

  Al flashcards, explanations, exams and more...

• Ads-free access

  To over 500 millions flashcards

• Money-back guarantee

  We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

Research Methodology

Research methodology is crucial in designing and evaluating scientific studies. It refers to the systematic, theoretical analysis of the methods applied to a field of study. In the context of this study on Social Anxiety Disorder (SAD), the primary focus was determining whether ketamine can effectively treat SAD symptoms.

The researchers employed a variety of methodological approaches to answer this question. They conducted a double-blind, randomized, placebo-controlled crossover trial. This trial design is considered robust and is often used in medical research to evaluate the efficacy of treatments. The methodology aimed to reduce bias and increase the reliability of the results. Such methods allow for a comprehensive understanding and ensure that conclusions drawn from the study are well-supported. Properly designed research methodology can effectively isolate the treatment effects, providing confident statements about ketamine's efficacy in reducing anxiety.

Double-Blind Study

In this study, a double-blind design was utilized. A double-blind study means neither the participants nor the researchers know who is receiving the treatment or the placebo.

This approach is crucial to reduce bias. Blinding helps prevent any preconceptions from influencing the results or how they are reported by researchers or experienced by participants. Both the treatment with ketamine and the placebo were randomly assigned to 18 participants with Social Anxiety Disorder. This design helps ensure that any observed effects are due to the treatment itself and not external factors or expectations. Therefore, double-blind studies are considered gold standard in clinical trials as they enhance the credibility and validity of the findings.

Ketamine Treatment

Ketamine, originally used as an anesthetic, is being explored for its potential psychiatric benefits, including treating Social Anxiety Disorder.

In the study outlined, ketamine was administered intravenously to participants, and its effects were measured against a placebo. The interest in ketamine as a treatment for SAD stems from the need for more effective treatment options, as some patients find little relief from traditional methods. Within the study, ketamine led to a significant reduction in specific anxiety metrics, indicating its potential as a therapeutic agent. This innovative use of ketamine presents a breakthrough in how mental health conditions like SAD could be addressed and encourages further research into understanding its full benefits and mechanisms.

Anxiety Reduction

Anxiety reduction is a key goal in treating Social Anxiety Disorder, making it a central focus of this study. The researchers evaluated the effect of ketamine on reducing anxiety levels using precise measurement tools.

The study findings showed that participants treated with ketamine experienced a notable decrease in anxiety compared to those given a placebo. Specifically, the response rate on the Liebowitz Social Anxiety Scale (LSAS) showed significant improvement, highlighting ketamine's role in diminishing anxiety symptoms. This potential for anxiety reduction may offer hope for those struggling with SAD, providing a new avenue of treatment where other methods have fallen short. Reduction in anxiety is crucial for improving the quality of life for individuals with SAD.

Liebowitz Social Anxiety Scale

The Liebowitz Social Anxiety Scale (LSAS) is a widely used tool for assessing the severity of social anxiety. It measures anxiety levels in various social interactions and performance situations.

This study used the LSAS to evaluate the effectiveness of ketamine in reducing symptoms of Social Anxiety Disorder. The results showed a significant reduction in LSAS scores for participants who received ketamine compared to those who had the placebo. The LSAS is crucial for providing quantitative data that can objectively measure treatment impacts. Its consistent use in research provides a standardized way to assess changes in social anxiety symptoms, making it an invaluable resource in both clinical trials and individual patient assessments.